Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial

Olivia Wagemann, Haiyan Liu, Guoqiao Wang, Xinyu Shi, Tobias Bittner, Marzia A. Scelsi, Martin R. Farlow, David B. Clifford, Charlene Supnet-Bell, Anna M. Santacruz, Andrew J. Aschenbrenner, Jason J. Hassenstab, Tammie L.S. Benzinger, Brian A. Gordon, Kelley A. Coalier, Carlos Cruchaga, Laura Ibanez, Richard J. Perrin, Chengjie Xiong, Yan LiJohn C. Morris, James J. Lah, Sarah B. Berman, Erik D. Roberson, Christopher H. Van Dyck, Douglas Galasko, Serge Gauthier, Ging Yuek R. Hsiung, William S. Brooks, Jérémie Pariente, Catherine J. Mummery, Gregory S. Day, John M. Ringman, Patricio Chrem Mendez, Peter St. George-Hyslop, Nick C. Fox, Kazushi Suzuki, Hamid R. Okhravi, Jasmeer Chhatwal, Johannes Levin, Mathias Jucker, John R. Sims, Karen C. Holdridge, Nicholas K. Proctor, Roy Yaari, Scott W. Andersen, Michele Mancini, Jorge Llibre-Guerra, Randall J. Bateman, Eric McDadeShow 30 othersShow less